Aditxt, Inc. (ADTX) experienced an increase of 6.4% in the aftermarket. However, the last trading session closed at $1.72 with a decline of 1.71%.
AditxtScore for COVID-19 Launched
On 9th September 2021, SphereDX has announced a cooperation with AditxtScoreTM for COVID-19. The COVID-19 AditxtScore is a more comprehensive immune response monitoring instrument that records numerous combinations of antibody and neutralizing antibody responses against a variety of antigens. Moreover, this allows researchers to measure the intensity of a person’s immunological response to COVID-19.
In a number of local assisted care institutions, SphereDX performed a trial study installing the AditxtScore for COVID-19. The findings of testing 99 completely vaccinated people ranging in age from 63 to 99 revealed that 33.3 percent of those examined had a poor immune response. There was no discernible immunological response to COVID-19 in 8.1 percent of that group. Lastly, people with moderately to severely weakened immune systems should get a second dose of the mRNA COVID-19 vaccine, according to the CDC.
ADTX Announces Closing of $11 Million Registered Direct Offering
ADTX stated that it had completed an $11 million registered direct offering on 7th September 2021. However, it had paid a bridging loan to its acquisition target, fulfilling a crucial provision of the Letter of Intent (LOI). In addition, the Company reached an agreement with the holder of its outstanding convertible note. Under this, the parties agreed to waive certain rights with respect to the convertible note.
ADTX Announces Pricing of $11.0 Million Registered Direct Offering
On 26th August 2021, ADTX announced that it has decided to enter into definitive documentation with certain investment firms to acquire 4,583,334 shares of its common stock in a registered direct offering priced at the market under Nasdaq rules for gross revenue of nearly $11.0 million, before commissions and expenses.
Furthermore, in a concurrent tender offer, an investor would receive from the Company an unregistered license. This will be done to acquire one share of common stock for each share of common stock purchased. The warrants have a $2.53 per share exercise price and are exercisable for a five-year period beginning six months after issuance.
ADTX and Great Lakes Medical Laboratory Launch AditxtScore for COVID-19
ADTX announced a collaboration with Great Lakes Medical Laboratory, Inc. to make its AditxtScoreTM for COVID-19 available across Michigan. Firstly, the COVID-19 AditxtScore is a more complete immune response monitoring instrument. It analyses numerous combinations of antibody and neutralizing antibody responses against multiple antigens. Secondly, the intensity of an individual’s immune response to the SARS-CoV-2 virus may now be assessed.
Thirdly, GLML will make the AditxtScore for COVID-19 available throughout its six physical sites and mobile units in Michigan as part of the deal. Last but not least, Aditxt is continuing to extend its immune surveillance network across the country with this endeavor.